STOCKHOLM, Jan. 27, 2021 /PRNewswire/ -- BioArctic AB
(publ) (Nasdaq Stockholm: BIOA B) announced today that the European
Patent Office (EPO) has issued a decision to grant European patent
EP 2 448 968 B1 for novel antibodies that could be
developed into a treatment for Alzheimer's disease. The antibodies
target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are
linked to the company's project AD1503. The patent enters into
force on 27 January 2021 and expires
in 2030.
BioArctic's newly granted patent focuses on novel antibodies
which target pE3-Ab, a specific truncated form of amyloid beta.
Monomers of pE3-Ab are highly prone to aggregate, leading to the
formation of harmful soluble Ab aggregates which cause debilitating
cognitive and other symptoms in Alzheimer's disease.
The granted patent underlines BioArctic's commitment in the
brain diseases field in general and in Alzheimer's disease research
specifically. By focusing on additional forms of amyloid beta
species in the disease cascade, BioArctic broadens the company's
scope to affect the disease pathology in addition to lecanemab
(BAN2401) - the company's primary Alzheimer's disease drug
candidate currently in phase 3 - widening the field for future
treatment possibilities.
"We are pleased that our patent has been granted for these novel
antibodies. More than 30 million people around the world live with
Alzheimer's disease today and there is a large medical need. We
continue to work tirelessly to develop and give these patients
access to the treatments they deserve," said Gunilla Osswald, CEO, BioArctic. ---
For further information, please contact:
Gunilla Osswald, CEO, BioArctic
AB
E-mail: gunilla.osswald@bioarctic.se
Phone: +46 8 695 69 30
Oskar Bosson, Vice President
Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
This information was submitted for publication at
08:00 a.m. CET on January 27, 2021.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma
company focusing on disease-modifying treatments and reliable
biomarkers and diagnostics for neurodegenerative diseases, such as
Alzheimer's disease and Parkinson's disease. BioArctic focuses on
innovative treatments in areas with high unmet medical needs. The
company was founded in 2003 based on innovative research from
Uppsala University, Sweden. Collaborations with universities are
of great importance to the company together with its strategically
important global partners in the Alzheimer (Eisai) and Parkinson
(AbbVie) projects. The project portfolio is a combination of fully
funded projects run in partnership with global pharmaceutical
companies and innovative in-house projects with significant market
and out-licensing potential. BioArctic's Class B share is listed on
Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information
about BioArctic, please visit www.bioarctic.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioarctic/r/bioarctic-receives-european-patent-for-new-antibodies-targeting-alzheimer-s-disease,c3274347
The following files are available for download:
https://mb.cision.com/Main/9978/3274347/1363827.pdf
|
Release
|